Cbio A/S is a biopharmaceutical company dedicated to curing cancer patients by making T-cell based immunotherapies available for patients worldwide. We focus on the t-cell therapy, which is the most promising cell-based treatment for solid tumors.
Cbio’s mission is to develop and bring next-generation T-cell therapies to cancer patients worldwide.
Pursuing our mission, we are developing next generation T-cell therapies for solid tumors, accounting for 90% of all cancers. Our transformative new T-cell product – novoleucel – enables more patients to be treated due to its minimal invasiveness, a broader T-cell repertoire of more stemness-like (revitalized) T-cells, and armed against oxidative stress designed to further improve the clinical outcome and survival for late-stage cancer patients.
Søborg
Cbio is located in Søborg, Copenhagen, in a 1,000 m2 state-of-the-art facility holding a manufacturing authorization to produce cell-based Advanced Therapy Medicinal Products (ATMPs) for clinical use. The facility is hosting the Company’s research, development and manufacturing activities and has cleanroom facilities with a current capacity to produce T-cell products for up to 150 patients per year. Cbio is planning to further expand the cleanroom infrastructure in order to increase the capacity to up to 600 T-cell therapy patients per year.
Cbio and Prof. Rolf Kiessling's group at Karolinska Intitute in Stockholm is working together to advance T-cell therapy to clinical phase I/II testing in cervical cancer patients. Rolf Kiessling is worldwide recognized for his early discovery and name-giving of Natural Killer cells - one of the key pillars of today's understanding of the immune system. His interest in understanding the tumor micro environment and in particular the effect of oxidative stress on immune cells has led to the remarkable dicovery of how T-cells can be armed and still maintain their effector function even under hostile conditions.
Cbio has established a 3-year research collaboration with Krister Wennerberg’s group at the Biotech Research and Innovation Centre, University of Copenhagen (BRIC). The aim of the project is to improve the TIL therapy product, make the production process more scalable and potentially further improve Cbio’s proprietary TIL stimulator cocktail using high-throughput screening facilities at BRIC. The project is supported by the Innovation Fund Denmark through the industry PhD program.
Cbio is collaborating with Odense University Hospital with the aim to develop and pre-clinically optimize TIL products for colorectal, kidney, ovarian and pancreatic cancer patients. The collaboration entails 4 clinical departments as well as the Pathological Institute and is approved by the Ethical Committee from Region South Denmark. By combining Cbio’s unique knowhow on TIL stimulators and ways to also generate successful TIL products from less immunogenic tumors with Odense’s pathologist expertise, the aim is to develop TIL products for these four cancer indications that could be tested clinically at a later stage.